Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (Aug 2021)

Variances in BCG protection against COVID-19 mortality: A global assessment

  • Zouina Sarfraz,
  • Azza Sarfraz,
  • Krunal Pandav,
  • Sarabjot Singh Makkar,
  • Saman Hasan Siddiqui,
  • Gaurav Patel,
  • Tania Platero-Portillo,
  • Bishnu Mohan Singh,
  • Mohamed Iburahim Haja Maideen,
  • Deepika Sarvepalli,
  • Muzna Sarfraz,
  • Jose Cardona-Guzman,
  • Marcos A. Sanchez-Gonzalez,
  • Ivan Cherrez-Ojeda

Journal volume & issue
Vol. 24
p. 100249

Abstract

Read online

The BCG vaccine is known to impart nonspecific immunological benefits alongside conferring protection to tuberculosis in endemic regions. It is also known to protect against bladder cancer and other respiratory tract infections. During the coronavirus disease 2019 (COVID-19) pandemic, the BCG vaccine has gained attention due to its role in conferring protective immunity. We demonstrate the potential immunological protective mechanisms that play a role against COVID-19. We conduct a global assessment of the countries that have the highest and lowest mortality rates determined by an a priori methodology. Lastly, we discuss the potential limitations of incorporating BCG vaccines as potential strategies against COVID-19 and provide recommendations regarding their use in ongoing and future epidemics.

Keywords